Capital-efficient path to a licensing event.
LSMedical is raising pre-seed capital to complete preclinical work and reach Phase I — the key value-inflection point in contrast agent development.
Building the future standard for contrast imaging.
LSMedical is advancing the first universal contrast agent platform for CT and MRI — a single, safer alternative to two legacy standards across a market estimated at over $7.5 billion.
A single nanoparticle platform that replaces two legacy contrast standards — gadolinium and iodine — with one safer agent for both CT and MRI. Patent-pending, GMP-validated, and progressing through preclinical with a clinical and research network already in place across leading EU and US institutions.
A $7.5 billion global market — concentrated, undefended, and growing.
The global contrast agent market is dominated by gadolinium and iodine-based products developed decades ago. Regulatory and demographic pressure is opening space for a safer next-generation platform.
A narrow window between scientific readiness and strategic competition.
The underlying market drivers are addressed above. For investors, the more relevant question is why this is the right moment to back this team and this platform — rather than wait for incumbents or alternatives to emerge.
First-mover patent position
Patent-pending platform filed early enough to provide meaningful runway through Phase I and into strategic partnership.
Strategic partner appetite
Documented BD activity from contrast majors (Bayer, GE Healthcare, Bracco) actively seeking next-generation alternatives to legacy agents.
Capital-efficient development
Nanoparticle manufacturing infrastructure has matured. Bringing a novel agent to Phase I costs materially less than in previous decades.
No novel regulatory pathway
Approval follows the existing contrast agent framework. Recent gadolinium restrictions establish regulator appetite for safer alternatives.
What we've already built.
LSMedical has moved from concept to validated platform — with manufacturing, clinical partnerships, and institutional backing already in place.
- Proof of concept established through published in vitro data
- Patent-pending nanoparticle platform filed
- Preclinical pipeline active across EU and US institutions
- Selected for NATO DIANA 2026 cohort
- Backed by Health Founders Estonia
- Founding team with two decades of contrast research
- Clinical and research network engaged across EU and US
A staged path to commercial entry.
Capital-efficient development with a strategic partner anticipated at Phase II to fund late-stage trials and accelerate market entry.
Long-term defensibility built into the platform.
A combination of formal IP protection, proprietary manufacturing know-how, and platform extensibility forms the foundation of LSMedical's competitive moat.
Patent-pending platform
Core synthesis and contrast technologies under active intellectual property protection strategy across primary territories.
Manufacturing know-how
Highly specialised nanoparticle production and formulation expertise built over two decades of contrast research.
Platform extensibility
Future applications across targeted imaging, diagnostic enhancement, and next-generation contrast technologies.
Capital-efficient path with strategic monetisation at Phase II.
LSMedical's path to commercial value runs through licensing to a strategic partner at Phase II / III — preserving capital efficiency through preclinical and Phase I while building toward a high-leverage commercial exit.
- Healthcare investors
- Imaging companies
- Pharmaceutical partners
- Clinical collaborators
- Strategic manufacturing partners
- Preclinical expansion
- Toxicology studies
- GMP pathway development
- Regulatory preparation
- Strategic partnerships
Download the full LSMedical investor deck.
A complete walkthrough of the platform, market, science, and roadmap. Shared confidentially on request.